Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116220 · ClinicalTrials.gov registry record · Phase 3
Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer
A Phase 3 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 3
- Development phase
- 206
- Enrollment target
NCT00116220 is a Phase 3 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 206 participants.
The verdict
NCT00116220, a Phase 3 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 206 participants
- Enrollment target
Study Summary
This clinical study was to determine if the use of 6 months of total androgen suppression (hormonal therapy) when added to radiation therapy for localized-high risk prostate cancer would improve overall survival.
Interventions
- RADIATION External Beam Radiotherapy
- DRUG Flutamide (Eulexin) and Lupron or Zoladex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 1995-09 |
| Est. Completion | 2015-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00116220
The ClinicalTrials.gov registry entry for NCT00116220 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 206 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which External Beam Radiotherapy is the first listed.
NCT00116220 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00116220 about?
NCT00116220 is a clinical study titled "Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer". This clinical study was to determine if the use of 6 months of total androgen suppression (hormonal therapy) when added to radiation therapy for localized-high risk prostate cancer would improve overall survival.
What is the current status of trial NCT00116220?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 206 participants. The study started on 1995-09. Estimated completion is 2015-02.
What interventions are being tested in trial NCT00116220?
The interventions under investigation include: External Beam Radiotherapy (RADIATION), Flutamide (Eulexin) and Lupron or Zoladex (DRUG).
Who is sponsoring clinical trial NCT00116220?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.